Quantcast

Tag Archives: human genome sciences

GlaxoSmithKline wins takeover bid for Human Genome

U.K. drug maker GlaxoSmithKline has secured its takeover of longtime partner Human Genome Sciences after agreeing to pay more, a move to expand GSK’s drug portfolio in crucial areas: biologic drugs and treatments for the hundreds of millions of people ...

Read More »

Human Genome adopts ‘poison pill’ measure

ROCKVILLE — Biotech drugmaker Human Genome Sciences Inc.’s board has adopted a “poison pill” shareholder rights plan to ward off unsolicited takeover bids, and it also has rejected a buyout offer worth nearly $2.6 billion from British pharmaceutical giant GlaxoSmithKline ...

Read More »

GlaxoSmithKline in takeover bid for Human Genome

LONDON — GlaxoSmithKline PLC has made an offer to take over Rockville-based drug maker Human Genome Sciences Inc. which values the company at nearly $2.6 billion. GlaxoSmithKline, which has profit-sharing agreements with HGS on three drugs but a minimal shareholding, ...

Read More »

Human Genome rejects GlaxoSmithKline’s $2.59B bid

The decision by Rockville-based biotech drugmaker Human Genome Sciences Inc. to reject an unsolicited $2.59 billion takeover bid Thursday may increase the eventual sale price of the company, analysts said. The question is by how much. “For the most part, ...

Read More »

FDA scrutinizes benefit of long-awaited lupus drug

WASHINGTON — Federal health officials said Friday that the first new drug developed to treat lupus in decades relieves disease symptoms, but they questioned the significance of its benefits, which varied across difference patient groups. Human Genome Sciences is asking ...

Read More »

HGS to drop its drug for hepatitis C

Human Genome Sciences Inc. has decided to drop one of its three late-stage development drugs after feedback from the U.S. Food and Drug Administration indicated it was not likely to be approved. The company said Tuesday it would stop development ...

Read More »